JP7159307B2 - Ａｔｒキナーゼの複素環式阻害剤 - Google Patents

Ａｔｒキナーゼの複素環式阻害剤 Download PDF

Info

Publication number
JP7159307B2
JP7159307B2 JP2020523235A JP2020523235A JP7159307B2 JP 7159307 B2 JP7159307 B2 JP 7159307B2 JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020523235 A JP2020523235 A JP 2020523235A JP 7159307 B2 JP7159307 B2 JP 7159307B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
haloalkyl
membered heterocycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527174A (ja
JP2020527174A5 (enExample
Inventor
エミリア ディ フランチェスコ マリア
ジョーンズ フィリップ
ローレンス キャロル クリストファー
ブライアント クロス ジェーソン
ケサヴァ ヴィジャヤン ラマスワミ スヤンブ
ギャレット ジョンソン マイケル
ライブリー サラ
ラポイント デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chempartner Corp
The University of Texas System
Original Assignee
Chempartner Corp
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chempartner Corp, The University of Texas System filed Critical Chempartner Corp
Publication of JP2020527174A publication Critical patent/JP2020527174A/ja
Publication of JP2020527174A5 publication Critical patent/JP2020527174A5/ja
Application granted granted Critical
Publication of JP7159307B2 publication Critical patent/JP7159307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020523235A 2017-07-13 2018-07-13 Ａｔｒキナーゼの複素環式阻害剤 Active JP7159307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
US62/531,951 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (3)

Publication Number Publication Date
JP2020527174A JP2020527174A (ja) 2020-09-03
JP2020527174A5 JP2020527174A5 (enExample) 2021-08-12
JP7159307B2 true JP7159307B2 (ja) 2022-10-24

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523235A Active JP7159307B2 (ja) 2017-07-13 2018-07-13 Ａｔｒキナーゼの複素環式阻害剤

Country Status (23)

Country Link
US (3) US10392376B2 (enExample)
EP (1) EP3651768B1 (enExample)
JP (1) JP7159307B2 (enExample)
KR (1) KR102676822B1 (enExample)
CN (2) CN117466884B (enExample)
AU (1) AU2018301696B8 (enExample)
CA (1) CA3069693A1 (enExample)
DK (1) DK3651768T3 (enExample)
ES (1) ES2974334T3 (enExample)
FI (1) FI3651768T3 (enExample)
HR (1) HRP20240368T1 (enExample)
HU (1) HUE066043T2 (enExample)
IL (1) IL271930B (enExample)
LT (1) LT3651768T (enExample)
MX (1) MX2020000386A (enExample)
PH (1) PH12020500072A1 (enExample)
PL (1) PL3651768T3 (enExample)
PT (1) PT3651768T (enExample)
RS (1) RS65466B1 (enExample)
SI (1) SI3651768T1 (enExample)
SM (1) SMT202400106T1 (enExample)
WO (1) WO2019014618A1 (enExample)
ZA (1) ZA202000148B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021518344A (ja) * 2018-03-16 2021-08-02 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ａｔｒキナーゼの複素環式阻害剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
HRP20240368T1 (hr) * 2017-07-13 2024-08-30 Board Of Regents, The University Of Texas System Heterociklički inhibitori atr kinaze
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Ａｔｒ阻害剤としての置換ピロロピリジン
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
EP3967694A4 (en) * 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
EP4155307A4 (en) 2020-05-20 2023-09-13 Beijing Tide Pharmaceutical Co., Ltd. 2,4,6-TRIS-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
AU2021282122B2 (en) * 2020-05-29 2023-09-21 Wuxi Life Fountain Biotech Co., Ltd Fluoropyrrolopyridine compound and application thereof
IL299510A (en) * 2020-07-03 2023-02-01 Antengene Discovery Ltd Atr inhibitors and uses thereof
WO2022171034A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 作为hpk1抑制剂的双环类化合物及其应用
EP4332103A4 (en) * 2021-05-12 2025-09-03 Chia Tai Tianqing Pharmaceutical Group Co Ltd ATR INHIBITOR COMPOUND CONTAINING A SULFOXIMINE
WO2022262143A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
GB2703674A (en) * 2024-10-14 2026-08-05 Artios Pharma Ltd Novel composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101563340A (zh) * 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
JP2008115166A (ja) * 2006-10-10 2008-05-22 Daiichi Sankyo Co Ltd ピリジルフェニルメチルスルホン誘導体
JP2010523637A (ja) 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
WO2008144500A2 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives
JP2010533161A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
WO2009007750A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
KR101712576B1 (ko) * 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HRP20240368T1 (hr) 2017-07-13 2024-08-30 Board Of Regents, The University Of Texas System Heterociklički inhibitori atr kinaze
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021518344A (ja) * 2018-03-16 2021-08-02 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ａｔｒキナーゼの複素環式阻害剤
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤

Also Published As

Publication number Publication date
KR102676822B1 (ko) 2024-06-19
PH12020500072A1 (en) 2020-11-09
AU2018301696B8 (en) 2023-03-23
NZ761374A (en) 2025-10-31
CA3069693A1 (en) 2019-01-17
US10800769B2 (en) 2020-10-13
EP3651768A1 (en) 2020-05-20
US10392376B2 (en) 2019-08-27
AU2018301696A1 (en) 2020-02-27
HUE066043T2 (hu) 2024-07-28
CN117466884B (zh) 2026-07-24
HRP20240368T1 (hr) 2024-08-30
AU2018301696B2 (en) 2022-10-27
PL3651768T3 (pl) 2024-09-02
EP3651768A4 (en) 2021-04-07
WO2019014618A1 (en) 2019-01-17
EP3651768B1 (en) 2023-12-20
IL271930A (en) 2020-02-27
US20190016713A1 (en) 2019-01-17
PT3651768T (pt) 2024-03-20
AU2018301696A8 (en) 2023-03-23
CN111867590B (zh) 2023-11-17
US20200102296A1 (en) 2020-04-02
IL271930B (en) 2022-07-01
RS65466B1 (sr) 2024-05-31
US11434233B2 (en) 2022-09-06
JP2020527174A (ja) 2020-09-03
US20210047311A1 (en) 2021-02-18
SMT202400106T1 (it) 2024-05-14
SI3651768T1 (sl) 2024-05-31
MX2020000386A (es) 2020-08-06
DK3651768T3 (da) 2024-03-18
CN117466884A (zh) 2024-01-30
FI3651768T3 (fi) 2024-03-14
ES2974334T3 (es) 2024-06-26
ZA202000148B (en) 2024-08-28
LT3651768T (lt) 2024-04-25
KR20200028441A (ko) 2020-03-16
CN111867590A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
US11434233B2 (en) Heterocyclic inhibitors of ATR kinase
JP7290627B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
JP7341156B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
CN105189514A (zh) 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓
HK40028148A (en) Heterocyclic inhibitors of atr kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221012

R150 Certificate of patent or registration of utility model

Ref document number: 7159307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250